阻塞性睡眠呼吸暂停手术中全静脉麻醉与吸入麻醉的费用比较
回顾性分析2019年1月至2020年10月230例阻塞性睡眠呼吸暂停手术患者,比较全静脉麻醉(TIVA)与吸入麻醉的费用与时间。TIVA组药房和手术室费用较高,但上气道刺激器和悬雍垂腭咽成形术患者中TIVA组耗材费用较低,鼻手术恢复时间缩短18分钟。作者认为TIVA在阻塞性睡眠呼吸暂停手术中可能具有成本效益。
要点
- TIVA组鼻手术总费用较吸入麻醉组高286美元(P=0.035)。
- TIVA组上气道刺激器耗材费用较吸入麻醉组低419.50美元(P=0.007)。
- TIVA组鼻手术恢复时间较吸入麻醉组缩短18分钟(P=0.004)。
核心结论
- 在门诊阻塞性睡眠呼吸暂停手术中,TIVA增加药房和手术室费用,但通常被较低的耗材、麻醉和恢复室费用所抵消。
- TIVA组恢复时间缩短,作者认为TIVA在患者结局方面有获益,在阻塞性睡眠呼吸暂停手术中可能具有成本效益。
研究设计与样本
- 回顾性病历审查,纳入2019年1月至2020年10月全身麻醉下阻塞性睡眠呼吸暂停手术患者230例。
- 95例接受TIVA,135例接受吸入麻醉,获取手术当日各项服务费用。
主要发现
- TIVA鼻手术组总费用较吸入麻醉组高286美元(P=0.035)。
- TIVA在所有手术和阻塞性睡眠呼吸暂停严重程度中均产生显著更高的药房和手术室费用。
- TIVA组上气道刺激器耗材费用较吸入麻醉组低419.50美元(P=0.007),悬雍垂腭咽成形术耗材费用较吸入麻醉组低115.16美元(P=0.015)。
- TIVA组上气道刺激器恢复室费用有降低趋势(-111.09美元,P=0.063),鼻手术恢复室费用有降低趋势(-64.45美元,P=0.096),鼻手术麻醉费用有降低趋势(-36.67美元,P=0.054)。
- TIVA组鼻手术总恢复时间缩短18分钟(P=0.004),上气道刺激器缩短25分钟(P=0.043),悬雍垂腭咽成形术缩短27分钟(P=0.147)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare cost and time spent in surgical and postoperative courses in patients with obstructive sleep apnea (OSA) undergoing surgery with either total intravenous anesthesia (TIVA) or inhalational anesthesia. STUDY DESIGN: Retrospective chart review. METHODS: Retrospective review on patients undergoing surgery for OSA under general anesthesia from January 2019 to October 2020. Cost per service was acquired for the day of surgery. RESULTS: A total of 230 patients were included: 95 received TIVA; 135 received inhalation anesthesia. Total cost was significantly higher in the TIVA nasal surgery group by $286 (P = .035). TIVA produced significantly higher pharmacy and operating room costs across all surgeries and OSA severities. These increased costs were offset by significantly lower supply costs in upper airway stimulator (UAS, -$419.50; P = .007) and uvulopalatopharyngoplasty (UPPP, -$115.16; P = .015) patients receiving TIVA. In the TIVA cohort, there was a trend toward lower recovery room costs after UAS (-$111.09; P = .063) and nasal surgery (-$64.45; P = .096) and anesthesia costs after nasal surgery (-$36.67; P = .054). Total recovery time was reduced by 18 minutes (P = .004) for nasal surgery, 25 minutes (P = .043) for UAS, and 27 minutes (P = .147) for UPPP patients receiving TIVA. CONCLUSION: When used in an outpatient setting for patients with OSA, TIVA adds to pharmacy and operating room costs, but this is usually offset by lower supply, anesthesia, and recovery room costs. We found decreased recovery times in the TIVA cohort. TIVA has proven benefits in patient outcomes and can be cost-effective in OSA surgery. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:1487-1494, 2022.
引用
- Alnemri A, Sussman S, Estephan L, et al. Cost of Total Intravenous Anesthesia Versus Inhalation Anesthesia in Obstructive Sleep Apnea Surgery. Laryngoscope. 2022. PMID: 35234282. doi:10.1002/lary.30094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。